Skip navigation
PR Newswire

Statement from FDA Commissioner Scott Gottlieb, M.D., on the approval of a new formulation of buprenorphine and FDA's efforts to promote more widespread innovation and access to opioid addiction treatments

U.S. Food and Drug Administration (FDA) logoSILVER SPRING, Md., Nov. 30, 2017 /PRNewswire-USNewswire/ -- With the approval today of a monthly formulation of the drug buprenorphine for the treatment of opioid use disorder, patients have access to a new and longer-acting option for the treatment of opioid addiction. Millions of...